NewMarket Corporation Highlights 2025 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy NEU?
Source: Yahoo Finance
- Net Income Decline: NewMarket reported a net income of $418.7 million and earnings per share of $44.44 for 2025, down from $462.4 million and $48.22 in 2024, primarily due to an increased effective tax rate, indicating pressure on profitability.
- Petroleum Additives Sales Drop: Sales for petroleum additives reached $2.5 billion in 2025, down from $2.6 billion in 2024, with operating profit at $520.1 million, a decline from the record $591.9 million, reflecting market softness and strategic adjustments in low-margin businesses.
- Specialty Materials Growth: Specialty materials sales hit $182.5 million in 2025 with an operating profit of $4.7 million, significantly up from 2024, driven by acquisitions of AMPAC and Calca, showcasing expansion potential in high-tech materials.
- Strong Cash Flow Performance: The company generated robust cash flows in 2025, paying $105.9 million in dividends, repurchasing $77.2 million in stock, and reducing long-term debt by $87.9 million, resulting in a net debt to EBITDA ratio of 1.1, indicating solid financial management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEU
About NEU
NewMarket Corporation is a holding company operating through its subsidiaries, Afton Chemical Corporation (Afton), Ethyl Corporation (Ethyl), and American Pacific Corporation (AMPAC). The Afton and Ethyl companies develop, manufacture, blend, and deliver chemical additives that enhance the performance of petroleum products. AMPAC is a manufacturer of specialty chemicals used in solid rocket motors for the aerospace and defense industries. Its petroleum additives segment includes lubricant and fuel additives. Its specialty materials segment includes critical materials used in solid rocket motors for space launch and military defense applications. Ethyl provides contracted manufacturing and related services to Afton and to third parties and is a marketer of antiknock compounds in North America. The Company is also a producer of UltraPure and high-purity hydrazine, which are essential, mission-critical propellants that enable advanced aerospace and defense applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NewMarket Corporation Highlights 2025 Earnings Report
- Net Income Decline: NewMarket reported a net income of $418.7 million and earnings per share of $44.44 for 2025, down from $462.4 million and $48.22 in 2024, primarily due to an increased effective tax rate, indicating pressure on profitability.
- Petroleum Additives Sales Drop: Sales for petroleum additives reached $2.5 billion in 2025, down from $2.6 billion in 2024, with operating profit at $520.1 million, a decline from the record $591.9 million, reflecting market softness and strategic adjustments in low-margin businesses.
- Specialty Materials Growth: Specialty materials sales hit $182.5 million in 2025 with an operating profit of $4.7 million, significantly up from 2024, driven by acquisitions of AMPAC and Calca, showcasing expansion potential in high-tech materials.
- Strong Cash Flow Performance: The company generated robust cash flows in 2025, paying $105.9 million in dividends, repurchasing $77.2 million in stock, and reducing long-term debt by $87.9 million, resulting in a net debt to EBITDA ratio of 1.1, indicating solid financial management.
See More
NewMarket Corporation Highlights 2025 Earnings Report
- Revenue and Net Income Decline: In Q4 2025, net income was $81.3 million, or $8.65 per share, significantly down from $110.7 million and $11.56 per share last year, reflecting pressures from market softness and a higher effective tax rate.
- Petroleum Additives Sales Drop: Q4 2025 petroleum additives sales were $585.1 million, down from $626.1 million in Q4 2024, primarily due to a 6% decline in shipments and lower selling prices, leading to operating profit dropping to $106.8 million, impacting overall profitability.
- Specialty Materials Growth: Specialty materials sales reached $48.5 million in Q4 2025, up from $27.1 million last year, with operating profit increasing from $1.5 million to $7.3 million, showcasing the positive impact of AMPAC and Calca acquisitions.
- Cash Flow and Shareholder Returns: The company generated strong cash flows in 2025, paying $105.9 million in dividends and repurchasing $77.2 million in stock while reducing long-term debt by $87.9 million, demonstrating financial resilience amid an uncertain economic environment.
See More
NewMarket Reports Q4 Earnings with Decline in Revenue
- Earnings Highlights: NewMarket reported Q4 GAAP EPS of $8.65, maintaining stable profitability; however, revenue declined by 2.9% year-over-year to $635.4 million, indicating growth challenges faced by the company.
- Revenue Decline Reasons: The revenue drop is primarily attributed to weak market demand and increased competition, putting pressure on the company to maintain sales, which could impact future profitability and investor confidence.
- Cash Return Performance: Despite the revenue decline, NewMarket continues to provide strong cash returns, demonstrating effective capital management that may attract investors seeking stable income.
- Growth Outlook Analysis: Analysts suggest that NewMarket's earnings growth may face a ceiling, indicating a need for the company to identify new growth drivers to adapt to changing market conditions and maintain competitiveness.
See More
Neuren Pharmaceuticals' DAYBUE Expected to Reach $700 Million in Global Sales by 2028
- Sales Forecast: Neuren Pharmaceuticals anticipates that its prescription drug DAYBUE for Rett syndrome will achieve global net sales of $700 million by 2028, reflecting strong growth potential in the market.
- Patient Treatment: Since its U.S. launch, over 2,000 Rett patients have been treated with DAYBUE, with a 12-month treatment persistency increase of 55%, indicating high patient reliance and satisfaction with the drug.
- Market Expansion: The company continued to expand its U.S. customer-facing teams in the second quarter of 2025, further driving DAYBUE sales growth, which underscores its strategic focus on market penetration and customer service.
- New Product Launch: The DAYBUE STIX formulation is set to launch in the U.S. in the first quarter of 2026, with a full commercial rollout planned for the second quarter, marking a significant enhancement of the company's product line and competitive positioning.
See More
NewMarket Corp Shares Drop to $695.94, Oversold Signal Emerges
- Oversold Condition: NewMarket Corp's stock price fell to $695.94 on Tuesday, with an RSI reading of 29.7 indicating an oversold condition, suggesting potential buying opportunities for investors.
- Dividend Yield: Based on the current price of $704.44, NEU's annualized dividend of $12 per share translates to a yield of 1.70%, making it an attractive option for dividend investors seeking higher returns.
- Market Comparison: NEU's low RSI compared to the average RSI of 52.0 for covered dividend stocks suggests that recent heavy selling may be exhausting, drawing interest from bullish investors.
- Investor Strategy: While dividends are not always predictable, analyzing NEU's dividend history can assist investors in assessing the likelihood of continued payments, enabling more informed investment decisions.
See More
NewMarket (NYSE:NEU) Investors Achieve 36% Annual Growth Rate Over Past Three Years
Stock Performance: NewMarket Corporation's share price has increased by 137% over the last three years, with a recent 2.8% rise, indicating strong market sentiment aligned with its earnings per share (EPS) growth of 33% annually.
Total Shareholder Return: The total shareholder return (TSR) for NewMarket over the past three years is 151%, surpassing its share price return, largely due to dividends that have enhanced overall returns.
Recent Growth: NewMarket has delivered a 46% TSR in the last twelve months, suggesting improved business momentum compared to a 17% annualized return over the past five years.
Investment Considerations: While NewMarket shows promising returns, potential investors should be aware of one warning sign and consider insider buying trends before making investment decisions.
See More
NewMarket Corporation Highlights 2025 Earnings Report
- Net Income Decline: NewMarket reported a net income of $418.7 million and earnings per share of $44.44 for 2025, down from $462.4 million and $48.22 in 2024, primarily due to an increased effective tax rate, indicating pressure on profitability.
- Petroleum Additives Sales Drop: Sales for petroleum additives reached $2.5 billion in 2025, down from $2.6 billion in 2024, with operating profit at $520.1 million, a decline from the record $591.9 million, reflecting market softness and strategic adjustments in low-margin businesses.
- Specialty Materials Growth: Specialty materials sales hit $182.5 million in 2025 with an operating profit of $4.7 million, significantly up from 2024, driven by acquisitions of AMPAC and Calca, showcasing expansion potential in high-tech materials.
- Strong Cash Flow Performance: The company generated robust cash flows in 2025, paying $105.9 million in dividends, repurchasing $77.2 million in stock, and reducing long-term debt by $87.9 million, resulting in a net debt to EBITDA ratio of 1.1, indicating solid financial management.
See More
NewMarket Corporation Highlights 2025 Earnings Report
- Revenue and Net Income Decline: In Q4 2025, net income was $81.3 million, or $8.65 per share, significantly down from $110.7 million and $11.56 per share last year, reflecting pressures from market softness and a higher effective tax rate.
- Petroleum Additives Sales Drop: Q4 2025 petroleum additives sales were $585.1 million, down from $626.1 million in Q4 2024, primarily due to a 6% decline in shipments and lower selling prices, leading to operating profit dropping to $106.8 million, impacting overall profitability.
- Specialty Materials Growth: Specialty materials sales reached $48.5 million in Q4 2025, up from $27.1 million last year, with operating profit increasing from $1.5 million to $7.3 million, showcasing the positive impact of AMPAC and Calca acquisitions.
- Cash Flow and Shareholder Returns: The company generated strong cash flows in 2025, paying $105.9 million in dividends and repurchasing $77.2 million in stock while reducing long-term debt by $87.9 million, demonstrating financial resilience amid an uncertain economic environment.
See More
NewMarket Reports Q4 Earnings with Decline in Revenue
- Earnings Highlights: NewMarket reported Q4 GAAP EPS of $8.65, maintaining stable profitability; however, revenue declined by 2.9% year-over-year to $635.4 million, indicating growth challenges faced by the company.
- Revenue Decline Reasons: The revenue drop is primarily attributed to weak market demand and increased competition, putting pressure on the company to maintain sales, which could impact future profitability and investor confidence.
- Cash Return Performance: Despite the revenue decline, NewMarket continues to provide strong cash returns, demonstrating effective capital management that may attract investors seeking stable income.
- Growth Outlook Analysis: Analysts suggest that NewMarket's earnings growth may face a ceiling, indicating a need for the company to identify new growth drivers to adapt to changing market conditions and maintain competitiveness.
See More
Neuren Pharmaceuticals' DAYBUE Expected to Reach $700 Million in Global Sales by 2028
- Sales Forecast: Neuren Pharmaceuticals anticipates that its prescription drug DAYBUE for Rett syndrome will achieve global net sales of $700 million by 2028, reflecting strong growth potential in the market.
- Patient Treatment: Since its U.S. launch, over 2,000 Rett patients have been treated with DAYBUE, with a 12-month treatment persistency increase of 55%, indicating high patient reliance and satisfaction with the drug.
- Market Expansion: The company continued to expand its U.S. customer-facing teams in the second quarter of 2025, further driving DAYBUE sales growth, which underscores its strategic focus on market penetration and customer service.
- New Product Launch: The DAYBUE STIX formulation is set to launch in the U.S. in the first quarter of 2026, with a full commercial rollout planned for the second quarter, marking a significant enhancement of the company's product line and competitive positioning.
See More
NewMarket Corp Shares Drop to $695.94, Oversold Signal Emerges
- Oversold Condition: NewMarket Corp's stock price fell to $695.94 on Tuesday, with an RSI reading of 29.7 indicating an oversold condition, suggesting potential buying opportunities for investors.
- Dividend Yield: Based on the current price of $704.44, NEU's annualized dividend of $12 per share translates to a yield of 1.70%, making it an attractive option for dividend investors seeking higher returns.
- Market Comparison: NEU's low RSI compared to the average RSI of 52.0 for covered dividend stocks suggests that recent heavy selling may be exhausting, drawing interest from bullish investors.
- Investor Strategy: While dividends are not always predictable, analyzing NEU's dividend history can assist investors in assessing the likelihood of continued payments, enabling more informed investment decisions.
See More
NewMarket (NYSE:NEU) Investors Achieve 36% Annual Growth Rate Over Past Three Years
Stock Performance: NewMarket Corporation's share price has increased by 137% over the last three years, with a recent 2.8% rise, indicating strong market sentiment aligned with its earnings per share (EPS) growth of 33% annually.
Total Shareholder Return: The total shareholder return (TSR) for NewMarket over the past three years is 151%, surpassing its share price return, largely due to dividends that have enhanced overall returns.
Recent Growth: NewMarket has delivered a 46% TSR in the last twelve months, suggesting improved business momentum compared to a 17% annualized return over the past five years.
Investment Considerations: While NewMarket shows promising returns, potential investors should be aware of one warning sign and consider insider buying trends before making investment decisions.
See More
